OLUMIANT

Persaitnep is used to treat adults with romite arthritis for moderate cases of severes who have not met with the required response to one or more of the anti-orthic drug combinations of alpha-type tumor necrosis (TNF) Inhibitors).

Persaitnep can also be used alone, added to methotricsat, or non-biotic anti-disception anti-modifying antitheatic drugs (DMARDs).

When using a phersyteanep, the phersyteanep is used to use a pierce, the piersyteanep is used to use a pierce, and the pierci is used to use a pierce, so the piercetean is not used to use a particle, so the pierceanian is not used to use a particle, so the pierceanian is not used, so the phersytean is not used, so the piercai is used, the patient is exposed to an infection of less than 1,000 cells per m3, or hemoglobin is released, less than 8 g per delta.

The phersyteanb, the use of a phersyteanep, may increase liver enzymes, so liver function tests must be performed continuously after the start, the pyrsai is administered, the patient is exposed to a serious infection that may result in need to enter hospital for appropriate treatment, and the patient uses a purse purse, and a purse, is used in an effective prithate, and a prith.

Bersaitenep drug belongs to the category of anti-infectant medication for Inseme Jack.

The use of Persaithnep was approved by the American Food and Drug Authority for Romantoid arthritis in 2018.